Current Immunotherapeutic Strategies in Pancreatic Cancer
- 31 October 2007
- journal article
- review article
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 16 (4) , 919-943
- https://doi.org/10.1016/j.soc.2007.07.012
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70Journal of Translational Medicine, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- Dendritic Cell-based Full-length Survivin Vaccine in Treatment of Experimental TumorsJournal of Immunotherapy, 2007
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cellsThe Journal of Experimental Medicine, 2007
- Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II studyBritish Journal of Cancer, 2006
- TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha geneCancer Gene Therapy, 2002
- Candida albicansIs Phagocytosed, Killed, and Processed for Antigen Presentation by Human Dendritic CellsInfection and Immunity, 2001
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutationThe Lancet, 1995
- Preparation of Pancreatic Cancer-Associated Mucin Expressing CA19–9, CA50, Span-1, Sialyl SSEA-1, and Dupan-2Scandinavian Journal of Gastroenterology, 1991